Medical Advisory Council
Kyle Amber, MD
Chicago, IL
Rush Medical College
Donna Culton, MD, PhD
Chapel Hill, NC
University of North Carolina- Chapel Hill
Ron Feldman, MD, PhD
Atlanta, GA
Emory University
Tanya Gibson, DDS
Kansas City, MO
University of Missouri- Kansas City
Robert Kelsch, DMD
New York, NY
Long Island Jewish Medical Center, Hofstra North Shore-LIJ School of Medicine
M. Peter Marinkovich, MD
Stanford, CA
Stanford University
Diana Messadi, DDS, PhD
Los Angeles, CA
UCLA
Yoshiyuki Mochida, DDS, PhD
Boston, MA
Boston University
Angela Ritchie, DDS
Omaha, NE
University of Creighton
Animesh A. Sinha, MD, PhD
Buffalo, NY
State University of New York – Buffalo
Mary Tomayko, MD, PhD
New Haven, CT
Yale University
Annette Czernik, MD
New York, NY
Mount Sinai Dermatology
David Fivenson, MD
Ann Arbor, MI
Fivenson Dermatology
Andrew Fribley, MD, PhD
Detroit, MI
Wayne State University
Sergei Grando, MD, PhD, DSc
Irvine, CA
University of California-Irvine
Joel M. Laudenbach, DMD
Charlotte, NC
Atrium Health
Emanual Maverakis, MD
Sacramento, CA
UC Davis Health
Aimee Payne, MD, PhD
New York, NY
Columbia University
Nasser Said-Al-Naief, DDS, MS
Portland, OR
Oregon Health & Science University
Brittany Schultz, MD
Minneapolis, MN
University of Minnesota
Thomas Sollecito, DMD, FDS, RCSEd
Philadelphia, PA
Penn Medicine
Victoria Werth, MD
Philadelphia, PA
University of Pennsylvania
IPPF Corporate Council
In 2020, the IPPF launched the Corporate Council, a collection of top stake-holders that are committed to facilitating collaboration and information exchange among patients, the IPPF, key opinion leaders, health-related organizations, and industry. We believe that only through an open and cooperative collaboration among all stakeholders will we effectively be able to address issues facing the pemphigus and pemphigoid (P/P) community.
The IPPF Corporate Council focuses on three areas of emphasis: access, advocacy, and awareness. Within these focus areas, the IPPF Corporate Council develops and supports activities and programs that ensure the IPPF fulfills its mission of improving the quality of life for all people affected by P/P through early diagnosis and support.
Membership in the IPPF Corporate Council demonstrates an organization’s leadership and commitment to addressing the challenges facing our patients. Involvement in the Council also provides the IPPF with an extended network of expertise and insight to ensure that we continue to address the unmet needs of all patients.
The Corporate Council provides hope and support by:
- Enhancing awareness, knowledge, and attention of P/P in society and among key audiences
- Organizing the IPPF community to drive progress in advocacy, awareness, research, drug development, and access to care
- Encouraging an industry, academic, and community collaborative investment in, and development of, new/improved treatments and therapies
- Promoting more effective identification, diagnosis, and treatment of P/P to improve patient experience/outcomes
IPPF Corporate Council Members
